Atualizações do tratamento farmacológico do transtorno de ansiedade generalizada
DOI:
https://doi.org/10.25118/2236-918X-5-2-3Palavras-chave:
Transtorno de ansiedade generalizada, tratamento, ensaios clínicosResumo
O transtorno de ansiedade generalizada (TAG) é um transtorno crônico e prevalente, mas também um dos menos estudados entre os transtornos de ansiedade. Os antidepressivos inibidores seletivos da recaptação da serotonina (ISRS) e inibidores da recaptação da serotonina e noradrenalina (IRSN) são considerados medicamentos de primeira linha no tratamento de TAG, porém não são incomuns casos de refratariedade, intolerância ou a presença de contraindicações ao uso dessas subtâncias. Diversas substâncias, como a pregabalina e a quetiapina, surgem, então, como alternativas para o tratamento do TAG nesses casos, assim como para a substituição dos benzodiazepínicos como medicações adjuvantes aos antidepressivos.
Downloads
Referências
Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int. 2014;111:473-80.
Leonardo ED, Hen R. Anxiety as a developmental disorder. Neuropsychopharmacology. 2008;33:134-40.
Mochcovitch MD, da Rocha Freire RC, Garcia RF, Nardi AE. A systematic review of fMRI studies in generalized anxiety disorder: evaluating its neural and cognitive basis. J Affect Disord. 2014;167:336-42.
Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia E. New perspectives in glutamate and anxiety. Pharmacol Biochem Behav. 2012;100:752-74.
Allgulander C. Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry. 2010;23:37-42.
Baldwin DS, Waldman S, Allgulander C. Evidencebased pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2011;14:697-710.
Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883-92.
European Medicines Agency. Lyrica (pregabalin) [Internet]. 2013 [cited 2014 Jan 9]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000546/human_med_000894.jsp&mid=WC0b01ac058001d124
Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol. 2006;16:S128-33.
Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167:869.
Aliyev NA, Aliyev ZN. Valproate (depakinechrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebocontrolled study. Eur Psychiatry. 2008;23:109-14.
Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord. 2002;68:1-23.
Lalonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2011;31:326-33.
Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31:418-28.
Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012;27:40-54.
Mezhebovsky I, Mägi K, She F, Datto C, Eriksson H. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry. 2013;28:615-25.
Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest–activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. J Clin Psychiatry.2010;71:109-20.
Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:561-6.
Stein D, Ahokas A, Allgulander C, Soegaard J, Bitter I, Lehtmets A, et al. P01-181 - Longterm treatment with agomelatine: prevention of relapse in patients with generalised anxiety disorder over 6 months. Eur Psychiatry. 2011;26:181.
Levitan MN, Papelbaum M, Nardi AE. A review of preliminary observations on agomelatine in the treatment of anxiety disorders. Exp Clin Psychopharmacol. 2012;20:504-9.
Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, doubleblind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012;22:847-57.
Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29:217-26.
Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012;27:142-50.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria permite que o (s) autor (es) mantenha(m) seus direitos autorais sem restrições. Atribuição-NãoComercial 4.0 Internacional (CC BY-NC 4.0) - Debates em Psiquiatria é regida pela licença CC-BY-NC
